Zacks
0
All posts from Zacks
Zacks in Our Research. Your Success.,

Dermira (DERM) in Focus: Stock Gains 8.7% in Session

Dermira, Inc. DERM was a big mover last session, as the company saw its shares rise roughly 9% on the day.  The move came on solid volume with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $23.60 to $28.69 in the past one-month time frame.

None of the estimates for this Med-Drugs stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Dermira has a Zacks Rank #3 (Hold).

However, a better-ranked stock in the same space is Juniper Pharmaceuticals, Inc. JNP, sporting a Zacks Rank #1 (Strong Buy).

Is DERM going up? Or down? Predict to see what others think: Up or Down

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
 


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
JUNIPER PHARMA (JNP): Free Stock Analysis Report
 
DERMIRA INC (DERM): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research